To determine the efficacy of antistaphylococcal therapy, as assessed by clinical outcomes, in patients with cystic fibrosis.
How were differences between studies investigated?
The authors do not state how differences between the studies were investigated.
Results of the review
Thirteen clinical trials were included, of which 3 were RCTs (91 patients). One of the RCTs was reported as 2 studies with different outcomes on the same population.
Substantial heterogeneity was noted among trials. Nineteen different pharmacological treatments used 11 clinical and 6 laboratory outcome measures in 13 clinical trials. There was a large variation in the clinical outcomes assessed in the 3 RCTs; the only outcomes common to all 3 studies were weight and sputum clearance of S. aureus. The 3 RCTs studied continuous cephalexin versus continuous dicloxacillin (duration 2 months), or continuous versus intermittent therapy with a variety of antibiotics (duration 1 to 2 years). Clearance of S. aureus from sputum: 1 RCT with a maximum of 42 patients reported an increased clearance of S. aureus with continuous flucloxacillin, compared to intermittent use of a variety of antibiotics. One RCT used multiple antibiotics for both treatment arms and was considered to be difficult to interpret. The other RCT compared continuous cephalexin and continuous dicloxacillin and had a short-term follow-up (2 months). All 9 non-randomised trials reporting this outcome showed improved sputum clearance with antistaphylococcal therapy.
There was limited evidence on clinical and pulmonary function.
Authors' conclusions
Antistaphylococcal treatment achieves sputum clearance of S. aureus in patients with cystic fibrosis. Prophylactic antistaphylococcal treatment in young children with cystic fibrosis is likely to be of benefit. It remains to be determined whether the use of prophylactic versus intermittent antistaphylococcal therapy is associated with improved lung function and/or chest radiography scores, an increase in bacterial resistance, or earlier acquisition of Pseudomonas aeruginosa.
CRD commentary
The aims were stated. Full details of the search strategy were given. A narrative review was appropriate in view of the heterogeneity among studies. Inclusion criteria for studies were not clearly defined and it was unclear whether language restrictions were applied to primary studies. No details were given of the methods used to select primary studies or extract data. Validity was not assessed. More comprehensive details of the included studies would have been helpful, such as criteria used for diagnosis of cystic fibrosis, characteristics of participants, and methods used to ascertain outcomes. Results were not reported clearly, and were classified as 'positive' or 'no difference' without qualification. The evidence reported was not adequate to assess antistaphylococcal antibiotic therapy in cystic fibrosis. The authors' conclusion that further research is urgently required was supported by the review.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors consider that a large randomised clinical trial lasting approximately 2 years is urgently required to determine whether the use of prophylactic versus intermittent antistaphylococcal therapy is associated with improved lung function and/or chest radiography scores, an increase in bacterial resistance, or earlier acquisition of Pseudomonas aeruginosa.
